Construction of a Risk Screening Tool for New Psychoactive Substance Misuse Among Adolescents and Young Adults
Launched by WEI XIA, PHD · Nov 27, 2024
Trial Information
Current as of August 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on creating a tool to help identify young people who might be at risk of misusing new psychoactive substances, which are drugs that can have effects similar to illegal drugs. The study aims to understand how often this kind of drug misuse happens among young adults and adolescents and what factors contribute to it. By doing this, the researchers hope to develop a simple screening tool that can help spot those at risk, allowing for early support and prevention of future addiction issues.
To participate in this study, young people aged 14 to 35 who can read and communicate in Chinese are invited to join. Participants will be asked to complete a questionnaire about their experiences and behaviors related to drug use. This research is important as it seeks to create a reliable way to identify those who may need help, ultimately aiming to reduce the risk of addiction in the future. The study is not yet recruiting participants, so there will be more information available once it begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adolescents and young adults who were aged 14-35 years;
- • Adolescents and young adults could read and communicate in Chinese were invited to participate in this study
- Exclusion Criteria:
- • Adolescents and young adults who were unable to complete the questionnaire due to physical or psychological reasons.
About Wei Xia, Phd
Wei Xia, PhD, is a distinguished clinical trial sponsor with extensive expertise in clinical research and development. With a strong background in biomedical sciences, Dr. Xia has a proven track record of leading innovative studies aimed at advancing therapeutic interventions. His commitment to rigorous scientific methodologies and ethical standards ensures the integrity and reliability of clinical trials. Dr. Xia's collaborative approach fosters partnerships with academic institutions and industry stakeholders, driving forward the translation of research findings into impactful healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported